Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Condition:   Pulmonary Tuberculosis Interventions:   Drug: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS);   Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS);   Drug: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE);   Drug: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS) Sponsors:   Bill & Melinda Gates Medical Research Institute;   Global Alliance for TB Drug Development;   Janssen Pharmaceutica;   Otsuka Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials

Using SMS Reminders, Phone Calls and Money Incentives to Enhance Linkage to Care of Presumptive TB Patients in Uganda
Condition:   Tuberculosis Interventions:   Behavioral: SMS;   Behavioral: Phone call;   Behavioral: Mobile money incentive Sponsor:   Makerere University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 28, 2023 Category: Research Source Type: clinical trials